Tearsheet
Investment Highlights Market Valuation Price Chart Return vs. Risk About JNJ Interactive Breakdown Better Bets vs. JNJ Latest Trefis Analyses Trade Ideas Recent Active Movers More From Trefis Peer Financials Peer Growth & Margins Peer Valuation Peer Returns Peer Analyses FDIC Bank Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Insider Activity Industry Resource Links External Quote Links

Johnson & Johnson (JNJ)

Market Price (10/26/2025): $190.49 | Market Cap: $458.8 Bil
Sector: Health Care | Industry: Pharmaceuticals

Johnson & Johnson (JNJ)

Market Price (10/26/2025): $190.49
Market Cap: $458.8 Bil
Sector: Health Care
Industry: Pharmaceuticals

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow

0 Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 8.1%, Dividend Yield is 2.7%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 4.0%		 Trading close to highs
Dist 52W High is -1.7%, Dist 3Y High is -1.7%		 
1 Attractive operating margins
Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 26%		 Weak multi-year price returns
2Y Excs Rtn is -28%, 3Y Excs Rtn is -57%		 
2 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 26%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 20%, CFO LTM is 24 Bil, FCF LTM is 19 Bil		  
3 Low stock price volatility
Vol 12M is 19%		  
0 Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 8.1%, Dividend Yield is 2.7%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 4.0%
1 Attractive operating margins
Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 26%
2 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 26%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 20%, CFO LTM is 24 Bil, FCF LTM is 19 Bil
3 Low stock price volatility
Vol 12M is 19%
4 Trading close to highs
Dist 52W High is -1.7%, Dist 3Y High is -1.7%
5 Weak multi-year price returns
2Y Excs Rtn is -28%, 3Y Excs Rtn is -57%

Market Valuation & Key Metrics

JNJS&P 500
REVENUE GROWTHFAIR
Rev LTM ($ Bil)92.1
Rev Chg Q6.8%6.4%
Rev Chg LTM5.1%5.3%
Rev Chg 3Y Avg6.1%5.4%
PROFITABILITYGOOD
Op Inc LTM ($ Bil)24.1
CFO LTM ($ Bil)24.2
Net Inc LTM ($ Bil)25.1
Op Mgn LTM26.2%18.7%
CFO/Rev LTM26.3%20.5%
Net Inc Mgn27.3%12.7%
VALUATIONMODERATE
P/S5.03.3
P/CFO19.016.1
P/FCF24.620.9
P/E18.324.0
STABILITYGOOD
Debt/Equity0.100.21
Cash/Assets0.100.07

JNJ Stock

   
   
   
   
   
   
   

Return vs. Risk

Price Returns Compared

 202020212022202320242025Total [1]
Returns
JNJ Return11%11%6%-9%-5%35%54%
Peers Return10%34%23%-1%12%2%105%
S&P 500 Return16%27%-19%24%23%15%110%

Monthly Win Rates [3]
JNJ Win Rate50%58%58%50%42%78% 
Peers Win Rate48%58%65%38%52%49% 
S&P 500 Win Rate58%75%42%67%75%67% 

Max Drawdowns [4]
JNJ Max Drawdown-23%-2%-7%-16%-7%-2% 
Peers Max Drawdown-23%-7%-10%-23%-8%-17% 
S&P 500 Max Drawdown-31%-1%-25%-1%-2%-15% 

[1] Cumulative total returns since the beginning of 2020
[2] Peers: LLY, ABBV, MRK, PFE, BMY. See JNJ Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 10/24/2025 (YTD)

How Low Can It Go

Unique KeyEventJNJS&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-21.7%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven27.8%34.1%
2022 Inflation ShockTime to BreakevenTime to Breakeven705 days464 days
2020 Covid Pandemic2020 Covid Pandemic  
2020 Covid Pandemic% Loss% Loss-27.8%-33.9%
2020 Covid Pandemic% Gain to Breakeven% Gain to Breakeven38.6%51.3%
2020 Covid PandemicTime to BreakevenTime to Breakeven31 days148 days
2018 Correction2018 Correction  
2018 Correction% Loss% Loss-19.4%-19.8%
2018 Correction% Gain to Breakeven% Gain to Breakeven24.1%24.7%
2018 CorrectionTime to BreakevenTime to Breakeven597 days120 days
2008 Global Financial Crisis2008 Global Financial Crisis  
2008 Global Financial Crisis% Loss% Loss-35.5%-56.8%
2008 Global Financial Crisis% Gain to Breakeven% Gain to Breakeven55.0%131.3%
2008 Global Financial CrisisTime to BreakevenTime to Breakeven1319 days1480 days

Compare to LLY, ABBV, MRK, PFE, BMY


In The Past

Johnson & Johnson's stock fell -21.7% during the 2022 Inflation Shock from a high on 4/25/2022. A -21.7% loss requires a 27.8% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Johnson & Johnson (JNJ)

Interactive Breakdown

Johnson & Johnson Interactive Breakdown Analysis

Better Bets than Johnson & Johnson (JNJ)

 JNJBetter Performance than JNJ
MetricValueIndustry (Pharmaceuticals)
Rev Chg LTM5.1%LLY (36.8%), PFE (13.5%), ZTS (5.3%), CORT (25.7%), ACAD (14.4%)
Rev Chg 3Y Avg6.1%LLY (23.4%), CORT (22.7%), ALKS (9.2%), ACAD (27.9%), AMRX (10.4%)
Op Mgn LTM26.2%LLY (43.0%), MRK (31.2%), ZTS (37.5%), PBH (31.2%), INVA (47.7%)
CFO/Rev LTM26.3%MRK (29.1%), BMY (30.0%), ZTS (31.2%), JAZZ (32.2%), ALKS (34.6%)
FCF/Rev LTM20.3%MRK (23.1%), BMY (27.5%), ZTS (23.6%), JAZZ (30.3%), CORT (25.2%)
Total Yield8.1%MRK (11.1%), PFE (12.8%), BMY (11.6%), OGN (39.0%), AMPH (11.7%)
 JNJBetter Performance than JNJ
MetricValueAll Other Sectors
Rev Chg LTM5.1%NVDA (71.6%), AAPL (6.0%), MSFT (14.9%), GOOGL (13.1%), AMZN (10.9%)
Rev Chg 3Y Avg6.1%NVDA (92.0%), MSFT (12.5%), GOOGL (10.2%), AMZN (11.3%), META (13.0%)
Op Mgn LTM26.2%NVDA (58.1%), AAPL (31.9%), MSFT (45.6%), GOOGL (32.7%), META (42.9%)
CFO/Rev LTM26.3%NVDA (46.6%), AAPL (26.6%), MSFT (48.3%), GOOGL (36.0%), META (56.4%)
FCF/Rev LTM20.3%NVDA (43.6%), AAPL (23.5%), MSFT (25.4%), META (30.7%), AVGO (41.6%)
Total Yield8.1%XOM (9.7%), BABA (36.1%), WFC (9.3%), TM (2036.8%), CVX (9.5%)
 Best Bets In Health Care Sector
 JNJRPRX HALO CPRX LNTH PBH EW AVTR ILMN HCA THC
What You Pay           
P/E18.315.514.412.314.214.510.815.312.517.912.9
P/EBIT14.28.211.310.59.79.326.610.410.49.85.0
What You Get           
Rev Chg Q6.8%7.7%40.8%19.4%-4.1%-6.6%11.9%-1.1%-4.8%6.4%3.2%
Rev Chg LTM5.1%3.0%35.0%28.5%5.7%0.6%9.1%-2.3%-3.3%6.4%-1.1%
Rev Chg 3Y Avg6.1%0.8%35.5%49.9%34.3%0.8%3.0%-4.3%-3.0%6.6%2.7%
FCF/Rev 3Y Avg20.3%113.4%43.4%38.9%26.1%21.6%11.9%9.7%9.0%8.4%7.1%

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

TitleTopicDate
0DASHBOARDS  
1Johnson & Johnson Earnings Notes  
2Time To Buy Johnson & Johnson Stock?Buy or Fear 
3JNJ Delivers $157 Bil to Investors Over a Decade  
4ZTS, AMRX Look Smarter Buy Than Johnson & Johnson StockActionable 
5Johnson & Johnson Stock Rallied 7.1% - Have You Assessed the RiskReturn 
6Day 7 of Gains Streak for Johnson & Johnson Stock with 5.4% Return (vs. 32% YTD) [10/1/2025]Notification 
7Day 7 of Gains Streak for Johnson & Johnson Stock with 5.4% Return (vs. 32% YTD) [10/1/2025]Notification 
8Day 7 of Gains Streak for Johnson & Johnson Stock with 6.8% Return (vs. 32% YTD) [10/1/2025]Notification 
9Day 6 of Gains Streak for Johnson & Johnson Stock with 6.4% Return (vs. 31% YTD) [9/30/2025]Notification 
10Day 6 of Gains Streak for Johnson & Johnson Stock with 6.4% Return (vs. 31% YTD) [9/30/2025]Notification 
11ARTICLES  
12Johnson & Johnson Stock Capital Return Hits $157 Bil October 21st, 2025
13S&P 500 Stocks Trading At 52-Week High October 10th, 2025
14Large Cap Stocks Trading At 52-Week High October 10th, 2025
15ZTS Beats Johnson & Johnson Stock on Both Fronts – Lower Price, Higher Growth October 8th, 2025
16S&P 500 Stocks Trading At 52-Week High October 8th, 2025
Title
0DASHBOARDS
1Johnson & Johnson Stock Capital Return Hits $157 Bil
2S&P 500 Stocks Trading At 52-Week High
3Large Cap Stocks Trading At 52-Week High
4ZTS Beats Johnson & Johnson Stock on Both Fronts – Lower Price, Higher Growth
5S&P 500 Stocks Trading At 52-Week High
6ARTICLES
7Johnson & Johnson Earnings Notes
8Time To Buy Johnson & Johnson Stock?
9JNJ Delivers $157 Bil to Investors Over a Decade
10ZTS, AMRX Look Smarter Buy Than Johnson & Johnson Stock
11Johnson & Johnson Stock Rallied 7.1% - Have You Assessed the Risk
12Day 7 of Gains Streak for Johnson & Johnson Stock with 5.4% Return (vs. 32% YTD) [10/1/2025]
13Day 7 of Gains Streak for Johnson & Johnson Stock with 5.4% Return (vs. 32% YTD) [10/1/2025]
14Day 7 of Gains Streak for Johnson & Johnson Stock with 6.8% Return (vs. 32% YTD) [10/1/2025]
15Day 6 of Gains Streak for Johnson & Johnson Stock with 6.4% Return (vs. 31% YTD) [9/30/2025]
16Day 6 of Gains Streak for Johnson & Johnson Stock with 6.4% Return (vs. 31% YTD) [9/30/2025]

Trade Ideas

Select past ideas related to JNJ. For more, see Trefis Trade Ideas.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy09302025ADMAADMA BiologicsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		3.5%3.5%-4.6%
REGN_9302025_Dip_Buyer_ValueBuy09302025REGNRegeneron PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		2.8%2.8%-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG09262025HAEHaemoneticsDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap		6.4%6.4%-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper09192025WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		19.5%19.5%-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper09052025ISRGIntuitive SurgicalMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		17.1%17.1%-8.0%
JNJ_4302024_Monopoly_xInd_xCD_Getting_Cheaper04302024JNJJohnson & JohnsonMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		12.5%11.6%0.0%
Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy09302025ADMAADMA BiologicsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		3.5%3.5%-4.6%
REGN_9302025_Dip_Buyer_ValueBuy09302025REGNRegeneron PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		2.8%2.8%-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG09262025HAEHaemoneticsDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap		6.4%6.4%-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper09192025WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		19.5%19.5%-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper09052025ISRGIntuitive SurgicalMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		17.1%17.1%-8.0%
JNJ_4302024_Monopoly_xInd_xCD_Getting_Cheaper04302024JNJJohnson & JohnsonMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		12.5%11.6%0.0%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1VICRVicor57.5%87.2%
2INBXInhibrx Biosciences53.8%272.0%
3CLBCore Laboratories48.7%-2.4%
4BALYBallys46.2%6.8%
5MOFGMidWestOne Financial43.2%39.2%
6NUVBNuvation Bio42.2%82.3%
7CLOVClover Health Investments41.0%21.3%
8CELCCelcuity36.6%442.2%
9WGOWinnebago Industries33.6%-12.7%
10GTXGarrett Motion33.3%91.3%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1PMIPicard Medical-45.4%8328.6%
2ITGRInteger-30.4%-45.0%
3METCRamaco Resources-23.8%244.9%
4WRLDWorld Acceptance-18.6%25.6%
5ASMAvino Silver & Gold Mines-18.2%450.5%
6SESSES AI-17.6%15.5%
7SMPLSimply Good Foods-17.5%-48.0%
8TNGXTango Therapeutics-17.0%142.6%
9OKLOOklo-16.7%540.8%
10LENZLENZ Therapeutics-16.4%10.7%

1 Month Top Gainers

#TickerCompany1M RtnYTD Rtn
1WOLFWolfspeed1498.4%344.0%
2PRAXPraxis Precision Medicines253.2%126.1%
3NVTSNavitas Semiconductor116.1%294.1%
4SNDKSanDisk97.4% 
5UAMYUnited States Antimony90.3%578.5%
6GRALGRAIL85.2%400.8%
7BALYBallys82.9%6.8%
8ORKAOruka Therapeutics81.1%40.5%
9INBXInhibrx Biosciences79.9%272.0%
10CIFRCipher Mining77.2%345.3%

1 Month Top Losers

#TickerCompany1M RtnYTD Rtn
1VGVenture Global-35.7% 
2PMIPicard Medical-35.3%8328.6%
3SOCSable Offshore-33.7%-41.7%
4FWRDForward Air-28.9%-39.0%
5FLYFirefly Aerospace-28.5% 
6ITGRInteger-28.4%-45.0%
7USNAUsana Health Sciences-26.5%-42.0%
8HTZHertz Global-26.3%41.5%
9RCReady Capital-25.1%-50.3%
10ULHUniversal Logistics-24.8%-61.0%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1VICRVicor57.5%87.2%
2INBXInhibrx Biosciences53.8%272.0%
3CLBCore Laboratories48.7%-2.4%
4BALYBallys46.2%6.8%
5MOFGMidWestOne Financial43.2%39.2%
6NUVBNuvation Bio42.2%82.3%
7CLOVClover Health Investments41.0%21.3%
8CELCCelcuity36.6%442.2%
9WGOWinnebago Industries33.6%-12.7%
10GTXGarrett Motion33.3%91.3%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1PMIPicard Medical-45.4%8328.6%
2ITGRInteger-30.4%-45.0%
3METCRamaco Resources-23.8%244.9%
4WRLDWorld Acceptance-18.6%25.6%
5ASMAvino Silver & Gold Mines-18.2%450.5%
6SESSES AI-17.6%15.5%
7SMPLSimply Good Foods-17.5%-48.0%
8TNGXTango Therapeutics-17.0%142.6%
9OKLOOklo-16.7%540.8%
10LENZLENZ Therapeutics-16.4%10.7%

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Johnson & Johnson

Financials

JNJLLYABBVMRKPFEBMYMedian
NameJohnson .Eli LillyAbbVie Merck Pfizer Bristol-. 
Mkt Price190.40825.45227.9987.4924.7643.83138.94
Mkt Cap458.5741.2403.1219.6140.889.0311.3
Rev LTM92,14953,25858,32863,61663,83347,63660,972
Op Inc LTM24,14622,88213,69519,82116,6637,87018,242
FCF LTM18,679-5018,23914,72212,43813,08613,904
FCF 3Y Avg17,814-15620,27312,8999,30412,22512,562
CFO LTM24,20410,93819,28318,53415,18814,31016,861
CFO 3Y Avg23,2097,23021,15416,76612,58413,41915,093

Growth & Margins

JNJLLYABBVMRKPFEBMYMedian
NameJohnson .Eli LillyAbbVie Merck Pfizer Bristol-. 
Rev Chg LTM5.1%36.8%6.1%1.8%13.5%4.6%5.6%
Rev Chg 3Y Avg6.1%23.4%0.6%3.7%-12.4%0.5%2.1%
Rev Chg Q6.8%37.6%6.6%-1.9%10.3%-5.6%6.7%
QoQ Delta Rev Chg LTM1.7%8.7%1.7%-0.5%2.2%-1.4%1.7%
Op Mgn LTM26.2%43.0%23.5%31.2%26.1%16.5%26.2%
Op Mgn 3Y Avg26.4%35.6%27.2%22.6%20.2%17.3%24.5%
QoQ Delta Op Mgn LTM1.7%1.8%1.0%-0.8%1.8%4.3%1.7%
CFO/Rev LTM26.3%20.5%33.1%29.1%23.8%30.0%27.7%
CFO/Rev 3Y Avg26.4%17.8%37.5%27.2%18.8%28.9%26.8%
FCF/Rev LTM20.3%-0.1%31.3%23.1%19.5%27.5%21.7%
FCF/Rev 3Y Avg20.3%0.5%36.0%20.9%13.8%26.4%20.6%

Valuation

JNJLLYABBVMRKPFEBMYMedian
NameJohnson .Eli LillyAbbVie Merck Pfizer Bristol-. 
Mkt Cap458.5741.2403.1219.6140.889.0311.3
P/S5.013.96.93.52.21.94.2
P/EBIT14.241.768.410.710.511.012.6
P/E18.353.7107.113.413.116.417.3
P/CFO18.967.820.911.89.36.215.4
Total Yield8.1%2.5%3.7%11.1%12.8%11.6%9.6%
Dividend Yield2.7%0.7%2.8%3.7%5.2%5.5%3.2%
FCF Yield 3Y Avg4.4%0.1%7.3%5.1%5.7%12.4%5.4%
D/E0.10.10.20.20.40.60.2
Net D/E0.10.00.20.10.30.40.1

Returns

JNJLLYABBVMRKPFEBMYMedian
NameJohnson .Eli LillyAbbVie Merck Pfizer Bristol-. 
1M Rtn7.1%15.5%5.1%12.7%4.9%2.4%6.1%
3M Rtn14.0%1.8%20.7%4.3%-0.1%-8.3%3.0%
6M Rtn25.1%-6.3%24.5%7.9%12.0%-6.0%9.9%
12M Rtn22.2%-6.8%25.6%-12.7%-6.9%-11.4%-6.8%
3Y Rtn21.1%136.5%66.9%-2.8%-36.6%-32.8%9.2%
1M Excs Rtn4.3%12.7%2.2%9.9%2.1%-0.5%3.3%
3M Excs Rtn9.1%-3.9%15.5%-1.2%-4.4%-12.8%-2.6%
6M Excs Rtn2.2%-29.2%1.6%-15.1%-10.9%-28.9%-13.0%
12M Excs Rtn4.2%-24.6%8.9%-31.0%-24.2%-28.9%-24.4%
3Y Excs Rtn-57.1%73.2%-6.0%-81.2%-116.1%-113.4%-69.2%

Comparison Analyses

Financials

$ Mil | FY: 12/292025Q32025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q32023Q22023Q12022Q4
Period End9/28/20256/29/20253/30/202512/29/20249/29/20246/30/20243/31/202412/31/202310/1/20237/2/20234/2/20231/1/2023
Filing Date10/22/20257/24/20254/23/20252/13/202510/23/20247/25/20245/1/20242/16/202410/27/20237/31/20234/28/20232/16/2023
Key Financials Quarterly            
Total Revenue23,99323,74321,89322,52022,47122,44721,38321,39521,35121,51920,89419,939
Ebitda9,5158,74215,6075,9205,3777,8005,6846,8207,2388,4578055,789
Operating Income7,1966,8106,2993,8415,2786,6576,2734,6076,1986,3586,2463,906
Net Income5,1525,53710,9993,4312,6944,6863,2554,04926,0285,144-683,520
EPS2.142.304.571.431.121.951.351.6810.321.98-0.031.35
Key Financials TTM            
Total Revenue TTM92,14990,62789,33188,82187,69686,57685,64885,15983,70382,34884,84987,381
Ebitda TTM39,78435,64634,70424,78125,68127,54228,19923,32022,28921,95921,12427,960
Operating Income TTM24,14622,22822,07522,04922,81523,73523,43623,40922,70822,17422,28822,160
Net Income TTM25,11922,66121,81014,06614,68438,01838,47635,15334,62413,05412,72417,941
Growth Rates Quarterly            
Total Revenue Growth6.8%5.8%2.4%5.3%5.2%4.3%2.3%7.3%6.8%-10.4%-10.8%104.1%
EBITDA Growth77.0%12.1%174.6%-13.2%-25.7%-7.8%606.1%17.8%4.8%11.0%-89.5%84.3%
Operating Income Growth36.3%2.3%0.4%-16.6%-14.8%4.7%0.4%17.9%9.4%-1.8%2.1%348.5%
Net Income Growth91.2%18.2%237.9%-15.3%-89.6%-8.9%4886.8%15.0%483.8%6.9%-101.3%-25.7%
Margins Quarterly            
EBITDA Margin39.7%36.8%71.3%26.3%23.9%34.7%26.6%31.9%33.9%39.3%3.9%29.0%
Operating Income Margin30.0%28.7%28.8%17.1%23.5%29.7%29.3%21.5%29.0%29.5%29.9%19.6%
Net Income Margin21.5%23.3%50.2%15.2%12.0%20.9%15.2%18.9%121.9%23.9%-0.3%17.7%
Cash & Debt            
Total Cash18,56218,88038,78124,52220,29725,47526,21822,92723,51128,50524,61322,281
Total Debt45,79550,76152,25236,63435,75141,49133,63229,33229,92145,60252,90739,642
Net Debt / (Cash)27,23331,88113,47112,11215,45416,0167,4146,4056,41017,09728,29417,361
Cash Flows Quarterly            
FCF from Operations9,1693,8784,1746,9837,9935,6333,6577,8637,4894,1823,2575,350
Cash Flows TTM            
FCF from Operations TTM24,20423,02824,78324,26625,14624,64223,19122,79120,27819,07320,47221,194
Returns to Shareholders Quarterly            
Dividends3,1323,1292,9892,9842,9852,9852,8692,8652,8713,0922,9422,954
Share Repurchases1,902-02,1272825391361,4752169203813,5371,320
Return on Invested Capital (ROIC) Quarterly            
ROIC64.6%67.1%129.7%112.0%110.3%135.5%296.6%246.3%319.5%45.1%17.3%25.0%
Return on Invested Capital (ROIC) TTM            
ROIC TTM62.9%53.2%115.5%153.4%123.7%124.5%269.0%323.4%312.6%40.9%35.4%35.7%

Segment Financials

Revenue by Segment

$ Mil20242023202220212020
Innovative Medicine54,75952,56351,68045,57242,198
MedTech30,40027,42727,06022,95925,963
Consumer Health  15,03514,05313,898
Total85,15979,99093,77582,58482,059


Assets by Segment
$ Mil20242023202220212020
MedTech74,71070,95653,37249,57849,462
Innovative Medicine58,32458,43664,37666,15856,292
General corporate34,52430,74939,18931,80325,356
Discontinued operations 27,237   
Consumer Health  25,08127,35526,618
Total167,558187,378182,018174,894157,728


Price Behavior

JNJ Betas & Captures as of 9/30/2025

 1M2M3M6M1Y3Y
Beta-0.09-0.090.070.140.060.15
Up Beta0.890.660.070.060.090.20
Down Beta-1.67-0.99-0.650.170.060.15
Up Capture43%41%81%25%8%3%
Bmk +ve Days13233574144420
Stock +ve Days11253770137396
Down Capture-75%-100%-61%16%-8%21%
Bmk -ve Days8192952107330
Stock -ve Days10172756114353

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date10152025
Short Interest: Shares Quantity20,626,892
Short Interest: % Change Since 930202513.5%
Average Daily Volume8,904,507
Days-to-Cover Short Interest2.32
Basic Shares Quantity2,408,300,000
Short % of Basic Shares0.9%

Returns Analyses

Earnings Returns History

Expand for More

 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
10/14/2025-0.0%1.5% 
7/16/20256.2%8.2%12.4%
4/15/2025-0.5%2.2%-5.2%
1/22/2025-1.9%1.5%8.6%
10/15/20241.5%0.8%-5.5%
7/17/20243.7%0.9%4.9%
4/16/2024-2.1%1.0%2.6%
1/23/2024-1.6%-1.9%-1.6%
...
SUMMARY STATS   
# Positive131711
# Negative11713
Median Positive2.7%2.2%4.9%
Median Negative-1.5%-2.0%-3.1%
Max Positive6.2%8.8%12.4%
Max Negative-2.8%-5.0%-6.3%

SEC Filings

Expand for More

Report DateFiling DateFiling
93020251022202510-Q 9/28/2025
6302025724202510-Q 6/29/2025
3312025423202510-Q 3/30/2025
12312024213202510-K 12/29/2024
93020241023202410-Q 9/29/2024
6302024725202410-Q 6/30/2024
3312024501202410-Q 3/31/2024
12312023216202410-K 12/31/2023
93020231027202310-Q 10/1/2023
6302023731202310-Q 7/2/2023
3312023428202310-Q 4/2/2023
12312022216202310-K 1/1/2023
93020221027202210-Q 10/2/2022
6302022729202210-Q 7/3/2022
3312022429202210-Q 4/3/2022
12312021217202210-K 1/2/2022

Insider Activity

Expand for More

 OwnerTitleFiling DateActionPriceSharesTransacted
Value		Value of
Held Shares		Form
0REED JOHN CEVP, Innovative Medicine, R&D7182025Sell163.5519,1373,129,8301,743,101Form
1WEINBERGER MARK A 12122024Buy147.221,000147,220147,220Form

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.